ereby revoke all previous powers of attorney CFR 3.73(b).	given in the a	pplication i	dentified in the	attached sta	tement under
ereby appoint:					
Practitioners associated with the Customer Number:	45511				
1 OR					
Practitioner(s) named below (if more than ten patent	practitioners are	to be named,	then a customer nu	mber must be	used):
Name	Registration . Na Number . Na		. Name	me Registra Numbe	
	IVOITORI				Manne
					-
		S			
itiomey(s) or agent(s) to represent the undersigned beli and all patent applications assigned <u>only</u> to the undersi ched to this form in accordance with 37 CFR 3.73(b).	igned according	the USPTO	essignment records	or assignmen	t documents
see change the correspondence address for the applica	tion identified in	the attached t	tatement under 37 (CFR 3.73(b) to:	
_					
The address associated with Customer Number:	4551	ı			
)R Trimor					
Individual Name					
ddress					
ly .	State			Zip	
ountry					
elephone		Email			
				763	
signes Name and Address:					
Janssen Pharmaceutica N.V. Turnhoutseweg 30					
Beerse, Belgium B-2340					
			and a set		
copy of this form, together with a statement used in each application in which this form is use	ad. The stater	nent under	37 CFR 3.75(b) n	ay be comp	leted by one o
e practitioners appointed in this form if the application in which this P				behalf of th	e assignee,
	ATURE of Assig				
The individual whose signature and titl	c is supplied bel	ow is authori	ed to act on behalf	of the assigned	
mature Manual Anadla			Dato	5-13-	^=
me Mary A. Appolling	A America				524-379
e Proxy Holder					
is collection of information is required by 37 CFR 1.31, 1.32 on the USPTO to process) an application. Confidentiality is gover- complete, including gathering: preparing, and submitting the co- mments on the amount of time you require to complete this for	4400 The State	allen is sometime	to secure as dealers		

U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1459, Alexandria, VA 22313-1480. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patente, P.O. Box 1459, Alexandria, VA 22313-1459.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: _JANSSEN PHARMACEUTICA N.V.	
Application No./Patent No.: _10/560,555 Filed/Issue Date: _December 12,	2005
Entitled: HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOETHYL)-PIPERIDINE BE	NZAMIDES AS 5HT4 ANTAGONISTS
JANSSEN PHARMACEUTICA N.V. , a <u>CORPORATION</u> (Name of Assignee, e.g., corporation,	partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest; or	
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is	
in the patent application/patent identified above by virtue of either:	
A A An assignment from the inventor(s) of the patent application/patent identified ab in the United States Patent and Trademark Office at Reel, Fram thereof is attached.	
OR B. A chain of title from the inventor(s), of the patent application/patent identified ab	ove, to the current assignee as follows:
1. From: INVENTORS J. BOSMANS AND J. GIJSEN To; JANSSEN PHARMACI The document was recorded in the United States Patent and Trademark Reel 017384 Frame 0.287 2. From: INVENTOR L. MEVELLEC To: JANSSEN-CILAG The document was recorded in the United States Patent and Trademark Reel 017384 Frame 0.292 , or for which a copy	Office at nereof is attached.
3. From: JANSSEN-CILAG To: JANSSEN PHARMACE	EUTICA N.V.
The document was recorded in the United States Patent and Trademark Reel 017364, Frame 0283, or for which a cop	Office at by thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of til assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s) Division in accordance with 37 CFR Part 3, to record the assignment in the n 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the a	ssignee.
/David N. Farsiou/	AUGUST 21, 2007
Signature	Date
David N. Farsiou	215-568-3100
Printed or Typed Name	Telephone Number
ATTORNEY FOR APPLICANT/REG. NO. 44,104	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any compete, including general ing, preparing, and sourmaing set competer displaced in an intervention in the Conference of the Conference of

ereby revoke all previous powers of attorney CFR 3.73(b).	given in the a	pplication i	dentified in the	attached sta	tement under
ereby appoint:					
Practitioners associated with the Customer Number:	45511				
1 OR					
Practitioner(s) named below (if more than ten patent	practitioners are	to be named,	then a customer nu	mber must be	used):
Name	Registration . Na Number . Na		. Name	me Registra Numbe	
	IVOITORI				Manne
					-
		S			
itiomey(s) or agent(s) to represent the undersigned beli and all patent applications assigned <u>only</u> to the undersi ched to this form in accordance with 37 CFR 3.73(b).	igned according	the USPTO	essignment records	or assignmen	t documents
see change the correspondence address for the applica	tion identified in	the attached t	tatement under 37 (CFR 3.73(b) to:	
_					
The address associated with Customer Number:	4551	ı			
)R Trimor					
Individual Name					
ddress					
ly .	State			Zip	
ountry					
elephone		Email			
				763	
signes Name and Address:					
Janssen Pharmaceutica N.V. Turnhoutseweg 30					
Beerse, Belgium B-2340					
			and a set		
copy of this form, together with a statement used in each application in which this form is use	ad. The stater	nent under	37 CFR 3.75(b) n	ay be comp	leted by one o
e practitioners appointed in this form if the application in which this P				behalf of th	e assignee,
	ATURE of Assig				
The individual whose signature and titl	c is supplied bel	ow is authori	ed to act on behalf	of the assigned	
mature Manual Anadla			Dato	5-13-	^=
me Mary A. Appolling	A America				524-379
e Proxy Holder					
is collection of information is required by 37 CFR 1.31, 1.32 on the USPTO to process) an application. Confidentiality is gover- complete, including gathering: preparing, and submitting the co- mments on the amount of time you require to complete this for	4400 The State	allen is sometime	to secure as dealers		

U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1459, Alexandria, VA 22313-1480. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patente, P.O. Box 1459, Alexandria, VA 22313-1459.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: _JANSSEN PHARMACEUTICA N.V.	
Application No./Patent No.: _10/560,555 Filed/Issue Date: _December 12,	2005
Entitled: HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOETHYL)-PIPERIDINE BE	NZAMIDES AS 5HT4 ANTAGONISTS
JANSSEN PHARMACEUTICA N.V. , a <u>CORPORATION</u> (Name of Assignee, e.g., corporation,	partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest; or	
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is	
in the patent application/patent identified above by virtue of either:	
A A An assignment from the inventor(s) of the patent application/patent identified ab in the United States Patent and Trademark Office at Reel, Fram thereof is attached.	
OR B. A chain of title from the inventor(s), of the patent application/patent identified ab	ove, to the current assignee as follows:
1. From: INVENTORS J. BOSMANS AND J. GIJSEN To; JANSSEN PHARMACI The document was recorded in the United States Patent and Trademark Reel 017384 Frame 0.287 2. From: INVENTOR L. MEVELLEC To: JANSSEN-CILAG The document was recorded in the United States Patent and Trademark Reel 017384 Frame 0.292 , or for which a copy	Office at nereof is attached.
3. From: JANSSEN-CILAG To: JANSSEN PHARMACE	EUTICA N.V.
The document was recorded in the United States Patent and Trademark Reel 017364, Frame 0283, or for which a cop	Office at by thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of til assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR	
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s) Division in accordance with 37 CFR Part 3, to record the assignment in the n 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the a	ssignee.
/David N. Farsiou/	AUGUST 21, 2007
Signature	Date
David N. Farsiou	215-568-3100
Printed or Typed Name	Telephone Number
ATTORNEY FOR APPLICANT/REG. NO. 44,104	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any compete, including general ing, preparing, and sourmaing set competer displaced in an intervention in the Conference of the Conference of